The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma

Abstract Diffuse large B-cell lymphoma (DLBCL) can be cured with standard front-line immunochemotherapy, whereas nearly 30–40% of patients experience refractory or relapse. For several decades, the standard treatment strategy for fit relapsed/refractory (R/R) DLBCL patients has been high-dose chemot...

Full description

Bibliographic Details
Main Authors: Tingxun Lu, Jie Zhang, Zijun Y. Xu-Monette, Ken H. Young
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Experimental Hematology & Oncology
Subjects:
Diffuse large B-cell lymphoma
Immunotherapy
Radiotherapy
Refractory
Relapsed
Online Access:https://doi.org/10.1186/s40164-023-00432-z

Internet

https://doi.org/10.1186/s40164-023-00432-z

Similar Items